18 October 2016 [07:00]

AstraZeneca today announced that the US Food and Drug Administration (FDA) has
accepted a complete re-submission of a New Drug Application (NDA) for sodium
zirconium cyclosilicate (ZS-9), a potential new medicine for the treatment of
hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a wholly
-owned subsidiary of AstraZeneca. The FDA has indicated that this is a complete
class 2 response.

Interactions with other health authorities in the European Union and Australia
are ongoing with decisions expected in the first half of 2017.

About sodium zirconium cyclosilicate (ZS-9) for oral suspension

Sodium zirconium cyclosilicate (ZS-9) is an insoluble, non-absorbed compound
with a structure that was designed to preferentially capture potassium ions.
Sodium zirconium cyclosilicate has been studied in three double-blind, placebo
controlled trials and in one ongoing 12-month open label clinical trial in
patients with hyperkalaemia which represents over 1,600 patients treated. Sodium
zirconium cyclosilicate is an investigational medicine that is not currently
approved for any indication in any market.

About hyperkalaemia

Hyperkalaemia (potassium levels > 5.0 mEq/L in the blood serum) commonly occurs
in patients with advanced chronic kidney disease and/or chronic heart failure,
and may lead to cardiac arrest and death. Treatment with common heart medicines
(RAAS inhibitors) can also be responsible for increases in hyperkalaemia.
Current therapeutic options are limited, leaving a high unmet medical need in
these patients.

About ZS Pharma
ZS Pharma was founded in 2008, became a public company in 2014 and, in December
2015, joined the AstraZeneca Group. ZS Pharma is focused on the development and
commercialisation of highly selective, non-absorbed drugs to treat renal,
cardiovascular and metabolic disorders. Additional information about ZS Pharma
is available at www.zspharma.com.

About AstraZeneca in Cardiovascular & Metabolic Disease (CVMD)

Cardiovascular, metabolic disease and chronic kidney disease are key areas of
focus for AstraZeneca as part of the company's strategy for achieving scientific
leadership and returning to growth. Our patient-led strategy is focused on
addressing the multiple risk factors facing CVMD and CKD patients at different
stages of their disease, with the goal of reducing morbidity and mortality
through life changing medicines.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on
the discovery, development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three main therapy areas - Oncology,
Cardiovascular & Metabolic Diseases and Respiratory. The Company also is
selectively active in the areas of autoimmunity, neuroscience and infection.
AstraZeneca operates in over 100 countries and its innovative medicines are used
by millions of patients worldwide. For more information, please visit
www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Enquiries
Neil Burrows         UK/Global           +44 203 749 5637
Vanessa Rhodes       UK/Global           +44 203 749 5736
Karen Birmingham     UK/Global           +44 203 749 5634
Rob Skelding         UK/Global           +44 203 749 5821
Jacob Lund           Sweden              +46 8 553 260 20
Michele Meixell      US                  +1 302 885 2677

Investor Relations
Thomas Kudsk Larsen                      +44 203 749 5712
Craig Marks          Finance, Fixed      +44 7881 615 764
                     Income, M&A
Henry Wheeler        Oncology            +44 203 749 5797
Mitchell Chan        Oncology            +1 240 477 3771
Lindsey Trickett     Cardiovascular &    +1 240 543 7970
                     Metabolic Diseases
Nick Stone           Respiratory         +44 203 749 5716
Christer Gruvris     Autoimmunity,       +44 203 749 5711
                     neuroscience &
US toll free                             +1 866 381 7277

Adrian Kemp

Company Secretary, AstraZeneca PLC